On June 15, the U.S. Food and Drug Administration (FDA) allowed marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old. The Neuropsychiatric EEG-Based Assessment Aid (NEBA) System is a 15- to 20-minute noninvasive test that calculates the ratio of theta and beta waves. The theta/beta ratio has been shown to be higher in children and adolescents with ADHD. Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder